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Abstract 
 
DTNBP1 (dystrobrevin binding protein 1) remains one of the top candidate genes 
in schizophrenia. Reduced expression of this gene and the protein it encodes, 
dysbindin-1, has been reported in the dorsolateral prefrontal cortex (DLPFC) of 
schizophrenia cases. It has not been established, however, if all dysbindin-1 
isoforms are reduced in the DLPFC or if the reduction is associated with reduced 
DTNBP1 gene expression. Using Western blotting of whole-tissue lysates of the 
DLPFC with antibodies differentially sensitive to the three major isoforms of this 
protein (dysbindin-1A, -1B, and -1C), we found no significant differences between 
our schizophrenia cases and matched controls in dysbindin-1A or -1B, but did 
find a mean 46% reduction in dysbindin-1C in 71% of 28 case-control pairs (p = 
0.022). This occurred in the absence of the one DTNBP1 risk haplotype for 
schizophrenia reported in the US and without alteration in levels of dysbindin-1C 
transcripts. Conversely, the absence of changes in the dysbindin-1A and -1B 
isoforms was accompanied by increased levels of their transcripts. We thus 
found no correspondence between alterations in dysbindin-1 gene and protein 
expression, the latter of which might be due to posttranslational modifications 
such as ubiquitination. Reduced DLPFC dysbindin-1C in schizophrenia probably 
occurs in PSDs, where we find dysbindin-1C to be heavily concentrated in the 
human brain. Given known postsynaptic effects of dysbindin-1 reductions in the 
rodent homolog of the prefrontal cortex, these findings suggest that reduced 
dysbindin-1C in the DLPFC may contribute to cognitive deficits of schizophrenia 
by promoting NMDA receptor hypofunction. 
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Introduction 
 
Since the initial report of Straub et al. in 2002,1 many studies have found that 
genetic variation in DTNBP1 (dystrobrevin binding protein 1) is associated with 
schizophrenia as reviewed by several investigators.2-4 Indeed, DTNBP1 remains 
among the top candidate genes for the disorder according to recent analyses.5,6 
DTNBP1 risk SNPs and haplotypes have been associated with a diverse group 
of cognitive deficits, which collectively form a core feature of schizophrenia.7-9 
Even in individuals without psychiatric illness, cognitive performance is worse in 
carriers of DTNBP1 risk SNPs than in non-carriers.10-12 The same is true for Sz 
cases carrying such SNPs. They show greater decline in general cognitive ability 
from a premorbid to a clinical state,13 lower general cognitive ability in the clinical 
state itself,10 lower scores on verbal, performance, and full-scale IQ tests on the 
Wechsler Adult Intelligence Scales-Revised,14, 15 deficits on a spatial working 
memory task and a Go NoGo attentional response task,16 and poor performance 
on Trail-Making Tests A and B.17 
 
DTNBP1 encodes the first known member of the dysbindin protein family, 
dysbindin-1,4 which is expressed in diverse neuronal populations throughout the 
brain.4, 18, 19 It is found in neuronal cell bodies, as well as pre- and post-synaptic 
sites in areas commonly affected in schizophrenia, such as the hippocampal 
formation and neocortex.4, 19 Postmortem studies on schizophrenia cases have 
found dysbindin-1 reductions in the hippocampal formation19 and dorsolateral 
prefrontal cortex (DLPFC),20 although the cited work on the latter area has not 
been fully reported. 
 
While not yet widely appreciated, there are multiple dysbindin-1 isoforms.  
We have designated the major isoforms as dysbindin-1A, -1B, and -1C in our 
characterization of the dysbindin protein family. 4 These are the protein products 
of the three most common DTNBP1 transcripts (i.e., NM_032122, NM_183040, 
and NM_183041 of the National Center for Biotechnology Information [NCBI], 
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respectively). We began to study these isoforms to determine which account for 
the observed dysbindin-1 reductions in schizophrenia. This is important because 
the isoforms are expected to play different neuronal roles as indicated by their 
differential distribution in synaptic and nuclear tissue fractions.4, 21 
 
We focus here on the DLPFC not only because that area is commonly 
affected in schizophrenia,22, 23 but also because all the cognitive tasks on which 
carriers of DTNBP1 risk SNPs perform poorly (see above) are mediated in part 
by the DLPFC. A role for the DLPFC in these cognitive tasks is evident in studies 
identifying brain regions involved in general cognitive ability,24, 25 IQ,25-27 spatial 
working memory,28-30 and mental flexibility.31, 32 
 
The present study is the first full report on dysbindin-1 protein expression 
and transcript-specific dysbindin-1 gene expression in the same schizophrenia 
cases. In such cases, we specifically investigated whether dysbindin-1 protein 
expression in the DLPFC is altered in an isoform-specific manner and if any such 
alteration is correlated with transcript-specific dysbindin-1 gene expression. We 
also tested if any observed alterations in dysbindin-1 isoforms or their transcripts 
occur in the absence of the DTNBP1 risk haplotype reported in a U.S. population 
by Funke et al.33  
 
Materials and methods 
  
Research Design and Subjects 
A matched-pairs design was used to compare fresh-frozen DLPFC tissue from 
28 Caucasian schizophrenia cases with 28 non-psychiatric Caucasian controls 
matched for sex and age within 5 years (Table 1). With the sole exception of a 
schizophrenia case with a 30 h postmortem interval (PMI) retained due to good 
protein and RNA preservation, all the cases had low PMIs (mean ± SD = 11.9 ± 
5.4 h for schizophrenia cases and 7.7 ± 3.8 h for controls). The schizophrenia 
cases had participated in a longitudinal study of prospectively diagnosed subjects 
approved by an Institutional Review Board at the University of Pennsylvania and 
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conducted by the University of Pennsylvania’s Schizophrenia Research Center 
as described previoulsy.34 Research autopsy consent was obtained from a family 
member or legal guardian in all cases. Psychiatric subjects met the diagnostic 
criteria for schizophrenia in the Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition (DSM-IV)35 as determined in consensus conferences 
following review of medical records, direct clinical assessments of the patients, 
and interviews with care providers. 
----------------------------------------------------------------------------------------- 
Place Table 1 about here 
----------------------------------------------------------------------------------------- 
Dysbindin-1 antibodies  
Dysbindin-1 isoforms in human DLPFC lysates were characterized using three 
polyclonal rabbit antibodies developed for use by our research group: Oxford 
PA3111A, UPenn 329, and UPenn 331 (Figure 1B). PA3111A was generated in 
Dr. Derek Blake’s laboratory at the University of Oxford. It was raised against a 
long C-terminus segment of mouse dysbindin-1 (amino acids 196-352) and has 
been characterized in earlier reports4, 18, 19 UPenn 329 was generated by Sigma 
Aldrich (St. Louis, MO, USA) against a synthetic peptide consisting of aa 313-326 
in the C-terminus region of human dysbindin-1A and -1C (NCBI accession nos. 
NP_115498 and NP_898862, respectively). UPenn 331 was also generated by 
Sigma Aldrich, but against a synthetic peptide consisting of aa 24-37 in the N-
terminus region of human dysbindin-1A and -1B (NCBI proteins NP_115498 and 
NP_898861, respectively). 
 
Quantification of DTNBP1 isoforms by Western immunoblotting 
Tissue was obtained at autopsy from the DLPFC (Brodmann areas 9 +46) and 
stored at -80°C (see Supplementary Information for description of methods of 
tissue collection and neuropathological assessment). Fresh frozen samples of 
the DLPFC were homogenized and lysed in RIPA buffer (Sigma) containing 150 
mM NaCl, 1.0% IGEPAL® CA-630 surfactant, 0.5% sodium deoxycholate, 0.1% 
SDS, 50 mM Tris (pH 8.0), a protease inhibitor cocktail (Sigma Aldrich P8340), 
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and EDTA at a final concentration of 1mM. After centrifugation at 10000g for 10 
min, the whole-cell supernatants were aliquoted and stored at -80oC. Protein 
concentrations were determined using a bicinchoninic (BCA) protein assay 
(Pierce Chemical, Thermo Fisher Scientific). 
 
Pilot studies indicated protein detection limits, the linear range of protein 
detection, and membrane exposure times for optimal quantification of protein 
concentrations. In accordance with those studies, 20 μg protein was loaded in 
each lane for electrophoresis. Protein samples were denatured in 5X Laemmli 
sample loading buffer (0.3 M Tris, 100 mg/ml SDS, 0.1 ml/ml 2-mercaptoethanol, 
0.5 ml/ml glycerol, 0.05 mg/ml bromophenol blue, pH 6.8) at 95oC. After boiling 
for 5 minutes, the samples were centrifuged at 16000 g for 5 min before loading 
on gels. To minimize interpretive errors resulting from variable transfer efficiency 
and immunoreactivity,36 samples from a schizophrenia case and its matched 
control were always run side-by-side on the same gel. To test reproducibility 
across blots, one or two reference samples were loaded on every gel; these 
reference samples were simply DLPFC lysates of a normal human case that 
yielded strong signals for dysbindin-1 isoforms in tests. Proteins were separated 
by SDS-polyacrylamide gel electrophoresis on precast 12% Tris-glycine 1.5 mm 
gels (Invitrogen Novex, Carlsbad, CA, USA). The separated proteins were then 
electroblotted onto a polyvinylidene difluoride (PVDF) transfer membrane (Bio-
Rad, Hercules, CA, USA) using a Novex XCell II Blot Module at 30 V for 2 h. 
 
 Two blots with the same samples were run concurrently. After rinsing with 
Tris-buffered saline in 0.1% Tween-20 (Sigma Aldrich), one blot was stained 
using the MemCode reversible protein stain kit (Pierce Chemical)37 to assess 
transfer efficiency and visualize protein loading. Relative amounts of total protein 
between 55 and 30 kDa were determined by optical density measurement in a 
GS-800 Bio-Rad calibrated densitometer. After de-staining and blocking with 5% 
wt/vol non-fat dry milk in PBST (phosphate buffered saline with 0.1% Tween 20) 
for 1 h, this first blot was incubated overnight at 4oC with the rabbit polyclonal 
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antibody Oxford PA3111A at a dilution of 1:1000 in TBS (with 5% milk and 0.1% 
Tween-20). The other blot was cut horizontally at the level of the 38 kDa marker: 
its top part was incubated with a mouse monoclonal β-actin antibody (Sigma 
Aldrich A1978) at a dilution of 1:12000, while the bottom was incubated with the 
rabbit polyclonal dysbindin-1 antibody UPenn 331 at a dilution of 1:6000. All the 
blots were reacted overnight at 4oC. Like Memcode staining, immunoblotting of 
β-actin served as a control for variable protein levels due to tissue storage time, 
sample preparation, protein loading, and transfer efficiency. After washing, 
immunoblots were incubated for 1 h at room temperature with horseradish-
peroxidase-linked secondary anti-rabbit or anti-mouse antibodies (Amersham 
Pharmacia/ GE Healthcare), developed via a chemiluminescence reaction (ECL 
or ECL plus kit, Amersham Biosciences), exposed to film (Amersham Hyperfilm 
ECL, GE Healthcare), and the bands quantified in a Bio-Rad densitometer. The 
immunoblotting experiments were repeated according to strictly standardized 
procedures to minimize variability in results across blots. 
 
Quantification of mRNA levels of DTNBP1 transcripts by quantitative reverse 
transcriptase-polymerase chain reaction (qRT-PCR) 
Total RNA was obtained from the same fresh frozen blocks of DLPFC tissue 
sampled for protein measurements. RNA was extracted using TRIZOL reagent 
(Invitrogen Life Technologies, Carlsbad, CA, USA). Yield and purity of RNA 
samples were determined by spectrophotometric analysis. 260/280 nm ratios of 
samples were > 2.1. Genomic DNA contamination was removed by treating 2 μg 
of each RNA sample with 40 U deoxyribonuclease (Sigma Aldrich) for 1 h at 
37oC. An Applied Biosystems (Foster City, CA, USA) high-capacity kit was used 
to synthesize cDNA from 20 μl of RNA from each sample by means of reverse 
transcriptase reactions. RNA extraction, DNA removal, and reverse transcriptase 
reactions were performed concurrently on all samples to be compared. 
 
DTNBP1 mRNA levels were measured using quantitative real-time 
polymerase chain reactions (qPCR) with primer pairs specified in Table S1. We 
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measured expression of three housekeeping genes (i.e., beta-2-microglobulin 
[B2M], glyceraldehyde-3-phosphate dehydrogenase [GAPDH], and hypoxanthine 
phosphoribosyl-transferase [HPRT]) as internal controls. The primer pairs used 
for the housekeeping genes are also specified in Table S1. 
 
Four primer pairs were designed to target DTNBP1 transcripts (Table S1 
and Figure 4A). Two of these, DYS-95 and DYS-102 (named for the size of the 
PCR product they yield), targeted most of the 16 DTNBP1 transcripts currently 
listed by AceView, including all those known in the DLPFC (DTNBP1 transcripts 
a-e, R. Straub, personal communication). The other two primer sets are selective 
for transcripts of either dysbindin-1B (DYS-d) or dysbindin-1C (DYS-e).   
 
qPCR was performed with an Applied Biosystems Prism 7900HT 
sequence detector system. A standard curve method was used to determine 
relative levels of gene expression.38, 39 Amplification of cDNA was performed on a 
pooled cDNA sample from human controls at different concentrations to define a 
linear range for all genes. Predicted sizes of PCR amplicons were verified by 
agarose gel electrophoresis. Amplification of selected reverse-transcriptase-
absent cDNA samples resulted in no detectable signal indicating minimal 
genomic DNA contamination. Once optimal reaction conditions were established, 
PCR amplification was performed in a total reaction volume of 20 μl with 2 μl 
cDNA (50 ng samples), 0.5 μM of each primer, and 10 μl of SYBR Green Master 
Mix (Applied Biosystems). The PCR cycling conditions were 50oC for 2 min, 95oC 
for 10 min, 40 cycles of 95oC for 15 s and 60oC for 10 min. All samples for a 
target transcript were measured in a single 384-well plate. All measurements 
were performed in triplicate.  
 
DTNBP1 genotyping  
DNA was obtained from fresh frozen brain tissue using the Gentra PUREGene 
cell kit (Qiagen, Valencia, CA, USA). Using a TaqMan 5’ exonuclease allelic 
discrimination assay (Applied Biosystems), the DNA was genotyped for a SNP 
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(P1578 = rs1018381) tagging a 6-SNP DTNBP1 risk haplotype for schizophrenia 
reported in a case-control study on US Caucasians.33  
 
Data analysis 
Western blotting. Comparisons of dysbindin-1 levels were naturally complicated 
by the fact that the number of samples exceeded the loading lanes of a single gel. 
We initially tried solving this problem by expressing optical density (OD) of bands 
as a percentage of one or two reference samples run on all blots. We discovered, 
however, that calibrating optical density measurements to reference samples did 
not yield values as reliable across blots as pair-wise ratios of each schizophrenia 
case to its matched control run on the same blot, as previously noted by Albert et 
al.40 We thus used two approaches. For analyses which did require comparison 
across blots (i.e., correlation of age, brain pH, and PMI with dysbindin-1 isoform 
levels in all samples), the OD of each band in a Western blot was divided by that 
of the reference sample (or samples) run on the same blot after normalizing for 
loading variations using β-actin levels. Averages of these values on the original 
and replication blots were used in correlational analyses. For analyses which did 
not require comparison across blots (i.e., Wilcoxon tests of differences within 
case-control pairs run on the same blot), we determined the OD for a dysbindin-1 
isoform in each schizophrenia case compared to its matched control run in an 
adjacent lane of the same blot using (a) raw OD data, (b) OD data normalized to 
β-actin, and (c) OD data normalized to density of MemCode staining. These OD 
ratios obtained from data on the original and replication blots were averaged and 
then log2 transformed such that a zero ratio reflected no difference between a 
schizophrenia case and its matched control, a negative ratio reflected a decrease 
in the schizophrenia case, and a positive ratio reflected an increase in that case. 
The log transformation permits use of the Wilcoxon signed ranks test for ratio 
data, because the log of a ratio between two values X/Y = logX - logY. 
 
qRT-PCR. Since all samples to be compared were run at the same time in 
one 384-well plate, data analysis was simplified compared to that for the Western 
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blotting data. Real-time PCR data acquisition and analysis were performed using 
SDS version 2.0 software (Applied Biosystems). Data points were omitted if they 
varied more than 1% from the mean of the triplicate samples based on raw cycle 
threshold values. In each experiment, the standard curve had a coefficient of 
determination (R2) > 0.996 and a slope between -3.32 and -3.57, which indicated 
an amplification efficiency of 91-100%. Negative controls comprising no-template 
cDNA yielded no detectable signal. An expression value for each reaction was 
quantified against a standard curve constructed from serial dilutions of the pooled 
cDNA. The relative expression value of dysbindin-1 mRNA was normalized to a 
geometric mean of the three internal control genes performed as suggested by 
Vandesompele et al.41 
 
Statistical analyses were performed with GraphPad Prism 3.0 software 
(GraphPad Software, La Jolla, CA, USA). Unpaired t-tests were used to assess 
statistical differences between schizophrenia cases and controls in demographic 
and autopsy variables (age, brain pH, and PMI). For Western blotting data, the 
non-parametric Wilcoxon signed-rank test was used to test if the log transformed 
pair-wise ratios were statistically different from the hypothetical median value of 
zero representing no significant differences between schizophrenia and control 
cases. For qRT-PCR data, the Wilcoxon signed-rank and unpaired t tests were 
used to test differences in PCR products between cases and matched controls. 
For comparison of case-control ratios of proteins and of transcripts, the Mann-
Whitney U test was used. The p values reported are two-tailed with p less than 
0.05 considered significant. 
 
Results 
 
Dysbindin-1 Isoforms in DLPFC 
According to NCBI’s Reference Sequence (RefSeq) database, a highly curated 
transcript collection,42 there are three validated splice variants of human DTNBP1 
mRNA among sixteen deduced DTNBP1 splice variants identified in the AceView 
database (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html). These 
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appear to be the most commonly expressed transcripts based on the number of 
cDNA clones available for their reconstruction. They encode dysbindin-1A, -1B 
and -1C (NCBI accession numbers NP_115498, NP_898861, and NP_898862, 
respectively). These proteins are the known isoforms of dysbindin-1, which along 
with dysbindin-2 and -3, constitute the dysbindin protein family,  all of whose 
members share a still poorly understood dysbindin domain (DD).4 The length and  
component parts of dysbindin-1 isoforms are indicated in Figure 1A. All have a 
coiled coil domain (CCD) important for certain protein-protein interactions but 
absent in dysbindin-2 and -3. Isoform A (351 aa in humans) is the full-length 
dysbindin-1 with a PEST domain at its C-terminus. Isoform B (303 aa), which is 
not expressed in the mouse, differs from isoform A only in its C-terminus region, 
which is shorter and lacks a PEST domain. In contrast, isoform C (270 aa) differs 
from isoform A only in the absence of an N-terminus region in front of its CCD. 
----------------------------------------------------------------------------------------- 
Place Figure 1 about here 
----------------------------------------------------------------------------------------- 
Using Oxford PA3111A, a well validated polyclonal antibody generated 
against the C-terminus region of dysbindin-1A (Figure 1B) ,18,19 we consistently 
detected three bands in Western blots of human DLPFC lysates at a dilution of 
1:1000 (Figure 1C), as we have in synaptosomal fractions of the human DLPFC, 
(Talbot et al., submitted). In an earlier study,19 we detected only two bands with 
PA3111A in lysates of human brain tissue. Detection of three bands with that 
antibody in our current studies may reflect use of larger protein samples (50 μg 
vs. 20-40 μg), higher percentage gels (12% vs. 10%), and more sensitive 
chemiluminescence detection kits. The three bands lay at about 48, 36, and 32 
kDa (Figure 1C). None of these bands were found when the antibody had been 
preadsorbed with the immunogen or with full-length dysbindin (i.e., dysbindin-1A). 
The heaviest band at about 48 kDa was readily identified as full-length dysbindin-
1, which has been reported to run at about 50 kDa.18,19,43 This is greater than the 
predicted 40 kDa mass of dysbindin-1A, probably due to its acidic nature4,43 and 
post-translational modification (i.e., phosphorylation4 and ubiquitination [Locke et 
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al., submitted]). The lighter bands at (36 and 32 kDa) are almost identical to the 
predicted molecular mass of dysbindin-1B and -1C (35 and 30 kDa, respectively). 
 
As shown in Figure 1C, the identity of the 48, 36, and 32 kDa bands seen 
with Oxford PA3111A were confirmed by results with other polyclonal antibodies. 
These were raised against synthetically derived peptide sequences in full-length 
dysbindin-1. One (UPenn 329), was raised against a 14 aa C-terminus sequence 
(aa 313-326) shared by dysbindin-1A and -1C, while the other (UPenn 331) was 
raised against a 14 aa N-terminus sequence (aa 24-37) shared by dysbindin-1A 
and -1B (Figure 1B). As the location of their immunogens predicted, UPenn 329 
recognized the top and bottom bands (i.e., dysbindin-1A and -1C), while UPenn 
331 recognized the top and middle bands (i.e., dysbindin-1A and -1B, Figure 1C). 
Even at a dilution of 1:6000, however, UPenn 331 had an unusually high avidity 
for dysbindin-1B with only low avidity for dysbindin-1A and no detectable avidity 
for dysbindin-1C (Figure 1C). The failure of UPenn 331 to recognize dysbindin-
1C is expected since its immunogen lies in the N-terminus region of dysbindin-1 
absent in dysbindin-1C. As these results indicate, UPenn 331 at the dilution used 
is a very sensitive and largely selective antibody for dysbindin-1B. It thus yields 
data complementary to Oxford PA3111A, which has a high avidity for dysbindin-
1A and -1C but apparently much lower avidity for dysbindin-1B judging from the 
weaker middle band seen in PA3111A blots (Figure 1C). For these reasons, we 
used Oxford PA3111A to detect dysbindin-1A and -1C, but UPenn 331 to detect 
dysbindin-1B.  
----------------------------------------------------------------------------------------- 
Place Figure 2 about here 
----------------------------------------------------------------------------------------- 
Dysbindin-1 Isoform Expression in DLPFC of Schizophrenia vs. Control Cases  
Representative results of Western blotting for dysbindin-1 isoforms in DLPFC of 
schizophrenia cases and matched controls are shown in Figure 2. As detailed in 
the Materials and Methods, such results enabled calculation of a ratio expressing 
the relative amount of each dysbindin-1 isoform in each of the 28 schizophrenia 
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cases compared to its matched control. A mean ratio was then calculated from 
the results on the original and replication blots. Log2 transformed mean ratios for 
all 28 pairs of schizophrenia and matched controls are graphed in Figure 3. The 
results were highly reproducible as indicated by strong correlations between the 
ratios obtained in the original and replication experiments for all dysbindin-1 
isoforms (e.g. Spearman r = 0.946, p = 9.2 x 10-14 for dysbindin-1A). 
 
For dysbindin-1A, the direction (plus or minus) and magnitude of the ratios 
were highly inconsistent. For dysbindin-1B, the ratios were also very inconsistent 
in direction, and their magnitudes were generally very small. Pair-wise analyses 
of each schizophrenia case to its matched control with the Wilcoxon signed-rank 
test accordingly showed no significant differences between schizophrenia and 
controls in levels of these two dysbindin-1 isoforms, which was the case whether 
raw or normalized data were used (n = 28, W = 78, p = 0.38 for dysbindin-1A; n = 
28, W = -12, p = 0.89 for dysbindin-1B). 
 
For dysbindin-1C, however, protein levels were reduced from 12-85% in 
the schizophrenia cases compared to matched controls in 20 out of the 28 pairs 
(71.42%). Unlike the case with the other two isoforms, pair-wise ratio analysis 
showed that dysbindin-1C in the DLPFC was significantly reduced in the DLPFC 
of our schizophrenia cases by an average of 46% (n = 28, W = 202, p = 0.0221). 
----------------------------------------------------------------------------------------- 
Place Figure 3 about here 
----------------------------------------------------------------------------------------- 
Dysbindin-1 Gene Expression in DLPFC of Schizophrenia vs. Control Cases 
To determine if the observed isoform-specific reduction in dysbindin-1 may be 
due to reductions in DTNBP1 gene expression, we measured the latter with qRT-
PCR using primer pairs specific for DTNBP1 transcripts in general (DYS-95 and -
102), for DTNBP1 transcript d (DYS-d) encoding dysbindin-1B, and for DTNBP1 
transcript e (DYS-e) encoding dysbindin-1C (see Table S1). Figure 4A shows the 
targets of the primers for DTNBP1 transcripts. Primers selective for dysbindin-1A 
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could not be designed since all sequences in that transcript are shared by many 
other DTNBP1 transcripts. However, results with the pan DTNBP1 primers DYS-
95 and -102 provide an estimate of dysbindin-1A transcript levels, because these 
are by far the most common dysbindin-1 transcripts in all tissues judging from 
Northern blotting results.4 Indeed, the amount of PCR product amplified with 
DYS-95 and -102 appeared to be far greater than that amplified with DYS-d or 
DYS-e as suggested by the much lower cycle threshold with DYS-95 and -102. 
 
In the same 28 case-control pairs in which relative dysbindin-1 isoform 
levels were measured, the schizophrenia cases showed significant increases in 
overall levels of DTNBP1 transcripts as measured with DYS-95 (t = 2.72, df = 54, 
p = 0.009) or DYS-102 (t = 2.77, df = 54, p = 0.008) and analyzed with unpaired 
t-tests (Figure 4B). Such tests also showed that the schizophrenia cases had 
significantly greater levels of dysbindin-1B transcripts measured with DYS-d (t = 
2.34, df =54, p = 0.023), yet normal levels of dysbindin-1C transcripts measured 
with DYS-e (t = 0.846, df = 54, p = 0.401) (Figure 4B). The statistical results was 
obtained in pair-wise analyses using the Wilcoxon signed-ranks test. Comparison 
of case-control ratios of dysbindin-1 transcripts and dysbindin-1 isoforms with the 
Mann-Whitney U test revealed no significant correlations between altered gene 
and protein expression in the schizophrenia cases. 
----------------------------------------------------------------------------------------- 
Place Figure 4 about here 
----------------------------------------------------------------------------------------- 
DTNBP1 Genotyping and Its Relation to DTNBP1 Gene and Protein Expression 
Only 2 controls and 2 schizophrenia cases were found to carry the rare allele of 
the P1578 SNP in DTNBP1 tagging a risk haplotype for schizophrenia in a US 
cohort.33 As a result, we were unable to test the effect of this haplotype on either 
gene or protein expression of DTNBP1. However, we were able to test if the 
observed differences between schizophrenia and control cases occurred in the 
absence of the haplotype. That proved to be the case. Exclusion of the case-
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control pairs with individuals carrying the rare allele of P1578 had no effect on 
the outcome of statistical analyses on dysbindin-1 isoforms or transcripts. 
 
Consideration of Potential Confounding Variables 
The observed dysbindin-1C reductions in schizophrenia cases were not readily 
attributed to non-diagnostic variables. Our schizophrenia and control groups had 
the same female/male ratio and did not differ significantly in age or brain tissue 
pH. While mean PMI was longer in the schizophrenia cases (11.9 ± 5.4 h) than in 
the controls (7.7 ± 3.8 h) (t = 3.46, df = 26, p = 0.0019), PMI (like age and brain 
tissue pH) was not significantly correlated with normalized levels of dysbindin-1 
proteins. Nor was there a significant correlation of normalized dysbindin-1 mRNA 
levels with PMI, age, or brain pH (apart from a negative correlation of dysbindin-
1B transcript with brain pH). Neither diagnostic group displayed any evidence of 
degenerative processes; neither showed evidence of gross cell loss, infarcts, or 
abnormally high densities of amyloid plaques, neurofibrillary tangles, or Lewy 
bodies. Finally, no significant correlations were found between any dysbindin-1 
isoform or transcript and the antipsychotic dosage of our schizophrenia cases in 
chlorpromazine equivalents one month prior to death, a finding in accordance 
with our study on dysbindin-1 in the hippocampal formation of such cases.19 This 
is also consistent with studies showing that chronic haloperidol administration to 
mice has no significant effect on dysbindin-1 gene44 or protein expression.19  
 
Discussion 
 
In this first report on dysbindin-1 isoforms in schizophrenia, we have discovered 
that DLPFC levels of dysbindin-1C, but not those of dysbindin-1A or -1B, are 
significantly altered. In particular, about 71% of our cases displayed 12-85% 
lower levels of disbindin-1C than did their matched controls. As detailed above, 
these results are not attributable to uncontrolled differences between diagnostic 
groups. While the present findings are based on whole-tissue lysates, we have 
found that dysbindin-1 is highly enriched in synaptic tissue fractions of both the 
mouse and human brain.4, 18, 21 While we find that some dysbindin-1 isoforms are 
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also enriched in cell nuclei of the brain, our studies show that dysbindin-1C in 
humans is concentrated primarily in postsynaptic density (PSD) fractions of the 
DLPFC and other brain areas studied so far (anterior cingulate gyrus, superior 
temporal gyrus and hippocampal formation, Talbot et al., submitted). Electron 
microscopic studies on tissue reacted with the Oxford antibody PA3111A have, in 
fact, found dysbindin-1 highly concentrated in some glutamatergic PSDs.4, 18 It is 
likely, then, that the observed reduction of DLPFC dysbindin-1C in schizophrenia 
occurs specifically in PSDs of glutamatergic synapses. 
 
 This is the second study pointing to reduced dysbindin-1 as a synaptic 
abnormality in schizophrenia. Depending on the specific anatomic area studied, 
our previous immunohistochemical work with the Oxford PA3111A antibody 
indicated that presynaptic dysbindin-1 was reduced in a very similar proportion of 
schizophrenia cases compared to their matched controls.19 Our more recent 
Western blotting work on synaptosomal preparations with the antibodies used in 
this study show that the presynaptic reduction in the hippocampal formation is 
due principally to decreased dysbindin-1B associated with synaptic vesicles and 
that this is accompanied by a previously undetected reduction in postsynaptic 
dysbindin-1 due to a decrease in dysbindin-1C (Talbot et al., submitted). As in 
the DLPFC, dysbindin-1A levels were unaltered in the hippocampal formation. 
There is thus growing evidence for isoform-specific dysbindin-1 reductions in 
schizophrenia that vary across brain areas. 
 
 The cause(s) of reduced dysbindin-1C in the DLPFC of schizophrenia 
cases is unknown. Using a riboprobe that would hybridize with mRNAs of all the 
dysbindin-1 isoforms studied here, Weickert et al.45 found that DTNBP1 gene 
expression in schizophrenia cases was 15-20% lower in all DLPFC cell layers 
except layer IV. Using quantitative RT-PCR with primers specific for dysbindin-1 
transcripts, however, we did not replicate that finding using a larger case sample 
of different ethnicity with far lower PMIs (i.e., 28 Caucasian schizophrenia cases 
with PMIs of 11.9 ± 5.4 h in this study versus 14 predominantly African-American 
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schizophrenia cases with PMIs of 38.0 ± 21.9 h in the study of Weickert et al.45). 
Moreover, we found no correspondence between schizophrenia-related changes 
in DTNBP1 gene and protein expression in the DLPFC, both of which occurred in 
the absence of the one known DTNBP1 risk haplotype33 for schizophrenia in the 
US. The lack of correspondence in gene and protein expression changes was 
striking. In the schizophrenia cases, overall levels of dysbindin-1 transcripts were 
elevated for unknown reasons, yet levels of the major encoded proteins were not. 
Levels of transcripts specific for dysbindin-1B were increased in schizophrenia 
cases, but levels of the isoform itself were not. Conversely, levels of transcripts 
specific for dysbindin-1C were normal in the schizophrenia cases, yet levels of 
dysbindin-1C protein were reduced. These findings indicate that factors other 
than DTNBP1 gene expression account for the observed reduction in dysbindin-
1C. Those factors are unknown, but may include posttranslational modifications 
promoting dysbindin-1C degradation such as phosphorylation and ubiquitination. 
 
 While the causes remain unknown, the consequences of lower dysbindin-
1C in the DLPFC are suggested by studies on sandy mice, which have a deletion 
mutation in Dtnbp1 resulting in loss of dysbindin-1A and -1C.4, 46 (Dysbindin-1B is 
not expressed in the mouse.4) As in humans, dysbindin-1A and -1C are abundant 
in PSD tissue fractions.21 In the rodent homolog of human prefrontal cortex (i.e., 
prelimbic cortex), homozygous sandy mice display (1) reduced NMDA receptor-
mediated glutamatergic input on deep layer pyramidal cells,47 (2) reduced NMDA 
receptor-mediated glutamatergic input on deep layer fast-spiking interneurons 
with associated reduction in their spike frequency, 48 and (3) reduced amplitude 
and frequency of spontaneous inhibitory postsynaptic currents in deep layer 
pyramidal neurons.49These findings suggest that loss of dysbindin-1A and/or -1C 
in the DLPFC can promote NMDA receptor hypofunction deep layer pyramidal 
neurons, which are glutamatergic, and at least a subpopulation of neighboring 
GABAergic interneurons. Reduced DLPFC dysbindin-1C in schizophrenia may 
thus contribute to the NMDA receptor hypofunction suggested in that disorder by 
an increasingly large number of studies.50, 51 
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It has been argued that in schizophrenia NMDA hypofunction in the 
parvalbumin-positive, fast-spiking interneurons of the DLPFC innervating initial 
axon segments of pyramidal neurons in the same brain area would reduce 
synchronized activity of the DLPFC and thereby disrupt processes important for 
working memory.52 The DLPFC is involved in several types of working memory, 
including spatial working memory,28,29  deficits in which are among the most 
common cognitive impairments in schizophrenia.7-9 Homozygous sandy mice, 
which lack dysbindin-1C, also display working memory deficits,53-55 including 
those detected on a non-matching to sample task sensitive to disruption of the 
rodent prefrontal cortex.53,54 It is possible, then, that reduced DLPFC dysbindin-
1C in schizophrenia may contribute to spatial working memory deficits in those 
cases by promoting NMDA receptor hypofunction in the parvalbumin-positive 
interneurons of the DLPFC. Testing that possibility requires much further work, 
however.  
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Variable Control Cases Schizophrenia Cases
Number of Cases 28 Caucasians 28 Caucasians
Mean Age ± SD 83.7 ± 9.0 y 81.7 ± 7.7 y
Gender Ratio: Female/Male 17/11 17/11
Mean PMI in Hours ± SD 7.7 ± 3.8 11.9 ± 5.4
Mean Brain Tissue pH ± SD 6.19 ± 0.04 6.46 ± 0.26
Table 1: Demographic and Autopsy Data on Cases Studied
1
1
There were no significant differences between control and schizophrenia
cases on any variable listed except PMI. As with age and pH, however, PMI
was not significantly correlated with levels of the proteins measured.
Primer Targeted Targeted Primer Sequence Product Protein Encoded
mRNA DTNBP1 (Forward/Reverse) Size by Targeted
(NCBI) Transcript (bp) mRNA
(AceView)
et al.
41
1
The two pan dysbindin-1 primers can recognize many DTNBP1 transcripts, including those for
dysbindin-1A, -1B, and -1C; they differ only in recognition of minor transcripts (AceView DTNBP1
transcripts i-m) not yet detected in the DLPFC. Of the DTNBP1 transcripts currently listed on AceView,
only a-e are known to be expressed in that brain area (R. Straub, personal communication).
2
The B2M (beta-2-microtubulin), HPRT1 (hypoxanthine phosphoribosyl-transferase 1), and GAPDH
(glyceraldehyde-3-phosphate dehydrogensase) primer sequences are described in Vandesompele
GAPDH
HPRT
2 NM_000194 ― 5'TGACACTGGCAAAACAATGCA3'/ 
5'GGTCCTTTTCACCAGCAAGCT3'
94 HPRT1
GAPDH
2 NM_002046 ― 5'TGCACCACCAACTGCTTAGC3'/ 
5'GGCATGGACTGTGGTCATGAG3'
87
Dysbindin-1C
B2M
2 NM_004048 ― 5'TGCTGTCTCCATGTTTGATGTATCT3'/ 
5'TCTCTGCTCCCCACCTCTAAGT3'
86 B2M
DYS-e NM_183041 e 5'AGTGAAAAGCAAACCCAGTTG3'/ 
5'GTCCTGCCCAAAAGAAACAC3'
66
pan Dysbindin-1(b)
1
DYS-d NM_183040 d 5'ACGCATAAACCCCCAAGC3'/ 
5'GACGGAACCACACCACTGT3'
96 Dysbindin-1B
DYS-102 NM_032122 a-i + k-m 5'CAGCAGGACATGGAGCAGTA3'/ 
5'CATGTCCACGTTCACTTCCA3'
102
Table S1: Primers Used for Quantitative RT-PCR
DYS-95 NM_032122 a-h + j 5'TCCCAGCTTTAATCGCAGAC3'/ 
5'CAGATGCAGCAGGTTGTTCT3'
95 pan Dysbindin-1(a)
1
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FIGURE LEGENDS 
 
Figure 1. Major dysbindin-1 isoforms in humans and their detection with three 
antibodies (Oxford PA3111A, UPenn 331, and UPenn 329). A compares the isoforms 
as characterized by Talbot et al.4 Numbers below isoforms designate amino acid (aa) 
sequence location beginning at the C-terminus. CCD = coiled coil domain composed of 
helices 1 and 2 (H1 and H2) separated by a stutter region (SR), CTR = carboxy 
terminus region, DD = the dysbindin domain, LZM = leucine zipper motif (LZM), NTR = 
amino terminus region, PD = PEST domain, and X1 and X2 are simply uncharacterized 
regions. B shows dysbindin-1A with the location of immunogens for Oxford PA3111A, 
UPenn 331, and UPenn 329. That for the Oxford antibody was aa 196-352 of mouse 
dysbindin-1A, which is 352 aa in length compared to 351 aa in humans. The UPenn 
antibodies were made to sequences indicated in human dysbindin-1A. C shows the 
dysbindin-1 isoforms recognized by Oxford PA3111A (1:1000), UPenn 331(1:6000), and 
UPenn 329 (1:40) in Western blots of whole-tissue lysates of the DLPFC lysates (50 μg 
per lane) from the same three normal humans as described in the Results. 
 
 
Figure 2. Representative Western blots showing relative amount s of dysbindin-1 
isoforms in the DLPFC of schizophrenia (S) cases compared to psychiatrically normal 
(N) controls matched for age and sex. Reference samples (R1 and R2) were run to 
assess differences across blots due to variations in experimental conditions. Numbers 
identify which of the 28 matched pairs tested is shown. 20 μg/lane of protein were 
electrophoresed, transferred to PVDF membrane, and probed with anti-dysbindin-1 
antibodies with Oxford PA3111 in A and C and with UPenn 331 in B. Blots were 
processed for β-actin (D) or MemCode staining (E) to control for variations in protein 
levels due to sample degradation during tissue storage, lysate preparation, gel loading, 
and/or to efficiency in membrane transfer.  
 
 
Figure 3. Levels of dysbindin-1A, -1B, and 1C in the DLPFC of schizophrenia cases 
compared to matched controls based on Western blotting analysis. Data are presented 
for all 28 case-control pairs studied along the X axis. For each of these pairs, the 
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amount of a dysbindin-1 isoform in the schizophrenia case to that in its matched control 
is expressed as a ratio shown on the Y axis. The ratio is actually the mean of ratios 
calculated in two separate series of Western blots on the same cases. The mean ratios 
were log transformed as explained in Data Analysis. Three bars are shown for each of 
the 28 case-control pairs: one for the mean ratio calculated with raw data (■), another 
calculated with data normalized to β-actin (⊟), and a third calculated with data 
normalized with MemCode results (□). The order in which case-control data is displayed 
from left to right varies in the three graphs; the series shown in each graph simply 
reflects rank ordering of the 28 pairs with increasingly positive ratios. Significant 
differences were found only for dysbindin-1C, in which 20 of the 28 matched pairs 
showed reductions in that protein (p = 0.0221). This finding was made with raw data and 
with data normalized to β-actin or MemCode staining. 
 
Figure 4. Targets of DTNBP1 primer sequences used in this study (A) and relative 
expression levels of the targeted DTNBP1 transcripts in DLPFC of schizophrenia (Sz) 
cases and matched normal (N) controls (B) as determined with qRT-PCR using primer 
sequences specified in Table S1. In A, the locations of the targeted RNA sequences are 
indicated in the 2007 AceView diagram of the exonic-intronic structure of the 16 known 
or deduced DTNBP1 pre-mRNA transcripts. Only transcripts a-e have been found in the 
DLPFC, however (R. Straub, personal communication). Boxed areas are exons, and the 
chevrons (⋀) between them are introns. Unshaded portions of exons are untranslated 
regions. NCBI accession numbers for mRNAs of dysbindin-1A, -1B, and -1C are given 
to the left of their transcripts. In B, relative levels of DTNBP1 transcripts are plotted for 
the 28 pairs of Sz and N cases in which their encoded proteins were also measured 
(Figure 3). For each of the four different transcripts, the data points (○) are normalized 
values divided by the mean expression level for that transcript on all samples (Sz and 
N) so that data for all four transcripts could be plotted on the same scale despite much 
higher levels of pan dysbindin-1 than dysbindin-1B or -1C transcripts. 




